Approval Alert | Luspatercept for Anemia Related to Low-Risk Myelodysplastic Syndrome

Luspatercept, which is supported by results from the phase 3 COMMANDS trial presented at 2023 ASCO, is now available for patients with low-risk myelodysplastic syndrome.

EP. 1: FDA Approves Frontline Luspatercept for Anemia Related to Low-Risk MDS

August 29th 2023

Luspatercept, the use of which is supported by results from the phase 3 COMMANDS trial presented at 2023 ASCO, is now available for patients with low-risk myelodysplastic syndrome and anemia.

EP. 2: Luspatercept Approval Helps to Improve Hemoglobin and QOL in MDS

ByNaval Daver, MD

August 29th 2023

Luspatercept, which is now FDA approved for myelodysplastic syndromes, may help patients achieve transfusion independence.

Approval Alert | Luspatercept for Anemia Related to Low-Risk Myelodysplastic Syndrome

EP. 1: FDA Approves Frontline Luspatercept for Anemia Related to Low-Risk MDS

EP. 2: Luspatercept Approval Helps to Improve Hemoglobin and QOL in MDS

Trending on CancerNetwork

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC

Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer

Case 2: Patient With High-Risk RRMM Relapsing After BCMA CAR T-Cell Therapy

Clinical Implications Remain After Dasatinib CRL in CML/ALL